Literature DB >> 17665184

Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease.

T Fiedler1, C Büning, W Reuter, G Pitre, E Gentz, H H Schmidt, J Büttner, J Ockenga, T Gerloff, C Meisel, H Lochs, I Roots, K Köpke, A Johne.   

Abstract

BACKGROUND: The role of the single nucleotide polymorphisms (SNPs) on positions 2677G>T/A and 3435C>T of the multi-drug-resistance gene 1 (MDR1) in inflammatory bowel disease (IBD) remains unclear. AIMS: To further elucidate the potential impact of MDR1 two-locus genotypes on susceptibility to IBD and disease behaviour. PATIENTS AND METHODS: Three hundred eighty-eight German IBD patients [244 with Crohn's disease (CD), 144 with ulcerative colitis (UC)] and 1,005 German healthy controls were genotyped for the two MDR1 SNPs on positions 2677G>T/A and 3435C>T. Genotype-phenotype analysis was performed with respect to disease susceptibility stratified by age at diagnosis as well as disease localisation and behaviour.
RESULTS: Genotype distribution did not differ between all UC or CD patients and controls. Between UC and CD patients, however, we observed a trend of different distribution of the combined genotypes derived from SNPs 2677 and 3435 (chi(2) = 15.997, df = 8, p = 0.054). In subgroup analysis, genotype frequencies between UC patients with early onset of disease and controls showed significant difference for combined positions 2677 and 3435 (chi(2) = 16.054, df = 8, p = 0.034 for age at diagnosis >or=25, lower quartile). Herein the rare genotype 2677GG/3435TT was more frequently observed (odds ratio = 7.0, 95% confidence interval 2.5 - 19.7). In this group severe course of disease behaviour depended on the combined MDR1 SNPs (chi(2) = 16.101, df = 6, p = 0.017 for age at diagnosis >or=25). No association of MDR1 genotypes with disease subgroups in CD was observed.
CONCLUSIONS: While overall genotype distribution did not differ, combined MDR1 genotypes derived from positions 2677 and 3435 are possibly associated with young age onset of UC and severe course of disease in this patient group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665184     DOI: 10.1007/s00228-007-0334-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study.

Authors:  Clive M Onnie; Sheila A Fisher; Reenal Pattni; Jeremy Sanderson; Alastair Forbes; Cathryn M Lewis; Christopher G Mathew
Journal:  Inflamm Bowel Dis       Date:  2006-04       Impact factor: 5.325

3.  ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach.

Authors:  G-T Ho; N Soranzo; E R Nimmo; A Tenesa; D B Goldstein; J Satsangi
Journal:  Hum Mol Genet       Date:  2006-01-24       Impact factor: 6.150

Review 4.  Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.

Authors:  V Annese; M-R Valvano; O Palmieri; A Latiano; F Bossa; A Andriulli
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis.

Authors:  B Yacyshyn; W Maksymowych; M B Bowen-Yacyshyn
Journal:  Hum Immunol       Date:  1999-08       Impact factor: 2.850

6.  In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms.

Authors:  Melanie Schaefer; Ivar Roots; Thomas Gerloff
Journal:  Pharmacogenet Genomics       Date:  2006-12       Impact factor: 2.089

7.  MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes.

Authors:  Kersti Oselin; Thomas Gerloff; Przemyslaw M Mrozikiewicz; Rein Pähkla; Ivar Roots
Journal:  Fundam Clin Pharmacol       Date:  2003-08       Impact factor: 2.748

8.  Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation.

Authors:  C Büning; J Genschel; S Bühner; S Krüger; K Kling; A Dignass; P Baier; B Bochow; J Ockenga; H H-J Schmidt; H Lochs
Journal:  Aliment Pharmacol Ther       Date:  2004-05-15       Impact factor: 8.171

9.  MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese.

Authors:  Tatsuya Osuga; Toshiyuki Sakaeda; Tsutomu Nakamura; Toshio Yamada; Tatsuya Koyama; Takao Tamura; Nobuo Aoyama; Noboru Okamura; Masato Kasuga; Katsuhiko Okumura
Journal:  Biol Pharm Bull       Date:  2006-02       Impact factor: 2.233

10.  P-glycoprotein increases from proximal to distal regions of human small intestine.

Authors:  Stéphane Mouly; Mary F Paine
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

View more
  17 in total

1.  Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Dhandapani Kayathiri; Subramanian Rajan; Deepak Gopal Shewade; Steven Aibor Dkhar; Sajjanavar Manjunath; Prayaga Ushakiran; Gangadharan Reneega; Kukreti Ritushree; Chandrasekaran Adithan
Journal:  Mol Biol Rep       Date:  2012-02-09       Impact factor: 2.316

Review 2.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

3.  Critical role for P-glycoprotein expression in hematopoietic cells in the FVB.Mdr1a(-/-) model of colitis.

Authors:  Elizabeth M Staley; Reed A Dimmitt; Trenton R Schoeb; Scott M Tanner; Robin G Lorenz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-12       Impact factor: 2.839

4.  ABCB1 3435C>T and 2677G>T/A polymorphisms in Polish and Bosnian patients with Crohn's disease - A preliminary report.

Authors:  Krzysztof Borecki; Iwona Zawada; Anna Pawinska-Matecka; Nermin Nusret Salkic; Beata Karakiewicz; Grażyna Adler
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

5.  MDR1 C3435T polymorphism and inflammatory bowel disease risk: a meta-analysis.

Authors:  Jun Wang; Xufeng Guo; Shijie Yu; Jixiang Zhang; Jia Song; Mengyao Ji; Zhuo Cao; Jing Wang; Ya Liu; Weiguo Dong
Journal:  Mol Biol Rep       Date:  2014-01-22       Impact factor: 2.316

Review 6.  Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature.

Authors:  Patricia Sarlos; Erzsebet Kovesdi; Lili Magyari; Zsolt Banfai; Andras Szabo; Andras Javorhazy; Bela Melegh
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

7.  Murine P-glycoprotein deficiency alters intestinal injury repair and blunts lipopolysaccharide-induced radioprotection.

Authors:  Elizabeth M Staley; Vanisha R Yarbrough; Trenton R Schoeb; Joseph G Daft; Scott M Tanner; Dennis Steverson; Robin G Lorenz
Journal:  Radiat Res       Date:  2012-07-10       Impact factor: 2.841

Review 8.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

9.  ABCB1 single nucleotide polymorphisms in the Brazilian population.

Authors:  Marcos Antonio Mauricio Scheiner; Arthur Motta Damasceno; Raquel Ciuvalschi Maia
Journal:  Mol Biol Rep       Date:  2009-05-13       Impact factor: 2.316

10.  Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults.

Authors:  Elizabeth M Staley; Trenton R Schoeb; Robin G Lorenz
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.